General news

Sylentis (PharmaMar Group) presents new results of tivanisiran for the treatment of dry eye disease	06/05/2019
Sylentis (PharmaMar Group) presents its new drug for retinal diseases at ARVO	03/05/2019
Sylentis (PharmaMar Group) at ARVO 2019 with results from two ophthalmic drugs: tivanisirán and SYL1801	25/04/2019
Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease	31/01/2019
Sylentis, PharmaMar Group, announces the end of patient recruitment for its HELIX trial	19/10/2018
The World Health Organization selects tivanisiran as the International Nonproprietary Name for SYL1001	19/10/2017
Sylentis sponsors the 11th OTS's Annual Meeting.	16/09/2015
Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics	17/11/2011
Sylentis, a pioneer in RNAi technology, obtains authorisation as research drug manufacturing laboratory	31/01/2011

Display #

We use our own and third-party cookies to provide a better service. If you continue to use this site, you are assumed to consent to the use of cookies.